Literature DB >> 25373630

A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

Michael H Rosenbloom1, Terry R Barclay, Maria Pyle, Brian L Owens, Amanda B Cagan, Christopher P Anderson, William H Frey, Leah R Hanson.   

Abstract

INTRODUCTION: Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insulin types.
OBJECTIVES: To measure the safety and efficacy of intranasally delivered RA glulisine in ApoE4 carriers with mild-moderate AD.
METHODS: We performed a double-blinded, randomized, cross-over study of RA insulin glulisine in nine mild-moderate AD subjects to better understand the relationship between RA insulin, ApoE4 carrier status and memory performance.
RESULTS: IN glulisine was well tolerated but failed to have an acute impact on cognition in ApoE4 carriers with AD. Serum insulin levels acutely dropped following treatment, but peripheral glucose levels remained unchanged.
CONCLUSION: Larger clinical trials of longer duration are necessary to better understand the relationships between RA insulin, ApoE4 carrier status and cognitive performance in AD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25373630     DOI: 10.1007/s40263-014-0214-y

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  16 in total

1.  Insulin to treat Alzheimer's disease: just follow your nose?

Authors:  Helgi B Schiöth; William H Frey; Samantha J Brooks; Christian Benedict
Journal:  Expert Rev Clin Pharmacol       Date:  2012-01       Impact factor: 5.045

2.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Intranasal insulin improves memory in humans.

Authors:  Christian Benedict; Manfred Hallschmid; Astrid Hatke; Bernd Schultes; Horst L Fehm; Jan Born; Werner Kern
Journal:  Psychoneuroendocrinology       Date:  2004-11       Impact factor: 4.905

Review 4.  The Bradford Hill criteria and zinc-induced anosmia: a causality analysis.

Authors:  Terence M Davidson; Wendy M Smith
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-07

5.  Characterization of the sniff magnitude test.

Authors:  Robert A Frank; Robert C Gesteland; Jason Bailie; Konstantin Rybalsky; Allen Seiden; Mario F Dulay
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-05

6.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

Authors:  Eric Steen; Benjamin M Terry; Enrique J Rivera; Jennifer L Cannon; Thomas R Neely; Rose Tavares; X Julia Xu; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2005-02       Impact factor: 4.472

7.  Anosmia after intranasal zinc gluconate use.

Authors:  Bruce W Jafek; Miriam R Linschoten; Bruce W Murrow
Journal:  Am J Rhinol       Date:  2004 May-Jun

8.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.

Authors:  Mark A Reger; G Stennis Watson; Pattie S Green; Laura D Baker; Brenna Cholerton; Mark A Fishel; Stephen R Plymate; Monique M Cherrier; Gerard D Schellenberg; William H Frey; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

Review 9.  Intranasal insulin to improve memory function in humans.

Authors:  Christian Benedict; Manfred Hallschmid; Bernd Schultes; Jan Born; Werner Kern
Journal:  Neuroendocrinology       Date:  2007-07-20       Impact factor: 4.914

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  23 in total

Review 1.  Routes for the delivery of insulin to the central nervous system: A comparative review.

Authors:  Elizabeth M Rhea; Therese S Salameh; William A Banks
Journal:  Exp Neurol       Date:  2018-11-27       Impact factor: 5.330

Review 2.  The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.

Authors:  John Grizzanti; Hyoung-Gon Lee; Antoni Camins; Merce Pallas; Gemma Casadesus
Journal:  Nutr Res       Date:  2016-11-08       Impact factor: 3.315

Review 3.  Relationship between cognitive function and regulation of cerebral blood flow.

Authors:  Shigehiko Ogoh
Journal:  J Physiol Sci       Date:  2017-02-03       Impact factor: 2.781

4.  Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin.

Authors:  Jill K Morris; Eric D Vidoni; Jonathan D Mahnken; Robert N Montgomery; David K Johnson; John P Thyfault; Jeffrey M Burns
Journal:  Neurobiol Aging       Date:  2015-12-01       Impact factor: 4.673

5.  A derangement of the brain wound healing process may cause some cases of Alzheimer's disease.

Authors:  Steven Lehrer; Peter H Rheinstein
Journal:  Discov Med       Date:  2016-08       Impact factor: 2.970

Review 6.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Authors:  Therese S Salameh; Elizabeth M Rhea; William A Banks; Angela J Hanson
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

7.  Novel calcium-related targets of insulin in hippocampal neurons.

Authors:  Shaniya Maimaiti; Hilaree N Frazier; Katie L Anderson; Adam O Ghoweri; Lawrence D Brewer; Nada M Porter; Olivier Thibault
Journal:  Neuroscience       Date:  2017-09-20       Impact factor: 3.590

Review 8.  Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Authors:  Konstantinos Ioannis Avgerinos; Grigorios Kalaitzidis; Antonia Malli; Dimitrios Kalaitzoglou; Pavlos Gr Myserlis; Vasileios-Arsenios Lioutas
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

9.  Impact of Single or Repeated Dose Intranasal Zinc-free Insulin in Young and Aged F344 Rats on Cognition, Signaling, and Brain Metabolism.

Authors:  Katie L Anderson; Hilaree N Frazier; Shaniya Maimaiti; Vikas V Bakshi; Zana R Majeed; Lawrence D Brewer; Nada M Porter; Ai-Ling Lin; Olivier Thibault
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-04-10       Impact factor: 6.053

10.  Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition.

Authors:  Therese S Salameh; Kristin M Bullock; Isabel A Hujoel; Michael L Niehoff; Tami Wolden-Hanson; Junghyun Kim; John E Morley; Susan A Farr; William A Banks
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.